ESSEXBIO-TECH：INTERIMREPORT2023.pdf

1、 INTERIM REPORT 2023 中期報告2023中期報告INTERIM REPORT 2023?SCIENCE&TECHNOLOGYPIONEERING GLOBALREGENERATIVETODAYTOMORROWS2Condensed Consolidated Statement of Proft or Loss and Other Comprehensive Income3Condensed Consolidated Statement of Financial Position4Condensed Consolidated Statement of Changes in Eq

2、uity5Condensed Consolidated Statement of Cash Flows7Notes to the Interim Condensed Consolidated Financial Statements23Management Discussion and Analysis40Additional Information44Corporate InformationCONTENTS2ESSEX BIO-TECHNOLOGY LIMITEDThe board(the“Board”)of directors(the“Directors”)of Essex Bio-Te

3、chnology Limited(the“Company”)presents the unaudited interim condensed consolidated financial statements of the Company and its subsidiaries(collectively,the“Group”)for the six months ended 30 June 2023 together with the comparative figures for the corresponding period in 2022 and the relevant expla

4、natory notes as set out below.CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOMEFor thesix monthsended 30 June20232022(Unaudited)(Unaudited)NotesHK$000HK$000 Turnover4&5899,359655,825Cost of sales(88,897)(69,181)Gross profit810,462586,644Other revenue,and other gains a

5、nd losses626,34824,081Distribution and selling expenses(520,663)(363,808)Administrative expenses(101,277)(79,564)Finance costs7(9,436)(4,652)Share of loss of an associate(579)Profit before income tax8204,855162,701Income tax9(35,044)(23,470)Profit for the period169,811139,231 Other comprehensive inc

6、omeItems that may be reclassified subsequently to profit or loss:Exchange differences on translation of financial statements of foreign operations(79,627)(78,111)Items that will not be reclassified subsequently to profit or loss:Changes in fair value of equity instruments at fair value through other